HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

von Hippel-Lindau disease: treatment of retinal haemangioblastomas by targeted therapy with systemic bevacizumab.

AuthorsWerner Wackernagel, Eva-Maria Lackner, Stefan Pilz, Christoph Mayer, Vinzenz Stepan
JournalActa ophthalmologica (Acta Ophthalmol) Vol. 88 Issue 7 Pg. e271-2 (Nov 2010) ISSN: 1755-3768 [Electronic] England
PMID20977691 (Publication Type: Case Reports, Letter)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
Topics
  • Angiogenesis Inhibitors (administration & dosage)
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Female
  • Hemangioblastoma (drug therapy, etiology)
  • Humans
  • Injections, Intravenous
  • Molecular Targeted Therapy
  • Retinal Neoplasms (drug therapy, etiology)
  • Young Adult
  • von Hippel-Lindau Disease (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: